At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill

Digital Health Program With Participants Using an Autoinjector

NCT06112184 ·Status: COMPLETED ·Phase: NA

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Tolerance and Patients' Satisfaction With IGHy

NCT03668288 ·Status: UNKNOWN

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

NCT00546871 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

NCT01581593 ·Status: COMPLETED ·Phase: PHASE3

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

NCT02783482 ·Status: COMPLETED ·Phase: PHASE3

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

NCT07123038 ·Status: RECRUITING

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

NCT00719680 ·Status: COMPLETED ·Phase: PHASE3

A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants

NCT02543918 ·Status: COMPLETED ·Phase: PHASE1

Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency

NCT03492710 ·Status: WITHDRAWN ·Phase: PHASE3

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

NCT00634569 ·Status: COMPLETED ·Phase: PHASE4

A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®

NCT02247141 ·Status: COMPLETED ·Phase: PHASE3

Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.

NCT00278954 ·Status: COMPLETED ·Phase: PHASE3

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05067127 ·Status: COMPLETED ·Phase: PHASE3

Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease

NCT07113743 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2

A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS

NCT01573533 ·Status: COMPLETED ·Phase: PHASE2

Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

NCT03939533 ·Status: COMPLETED ·Phase: PHASE3

A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)

NCT06305234 ·Status: RECRUITING

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

NCT07220915 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

NCT04565015 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment

NCT06159283 ·Status: RECRUITING ·Phase: PHASE2

Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients

NCT05013034 ·Status: UNKNOWN ·Phase: PHASE2

Rituximab for Anti-cytokine Autoantibody-Associated Diseases

NCT01842386 ·Status: COMPLETED ·Phase: PHASE1

Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

NCT01178216 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)

NCT05243680 ·Status: COMPLETED ·Phase: PHASE3